Minerva Neurosciences (NERV) Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant vs ... - StreetInsider.com

Submitted by Anonymous (not verified) on Thu, 12/21/2017 - 13:02

Minerva Neurosciences (NERV) Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant vs ...StreetInsider.comThe primary objective of this multi-center, double-blind, randomized, flexible-dose, parallel-group study is to assess the efficacy of flexibly dosed seltorexant compared to flexibly dosed quetiapine as adjunctive therapy to a baseline antidepressant ...and more »